Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, multicenter study comparing MDX-010 [ipilimumab] monotherapy, MDX-010 in combination with a melanoma peptide vaccine [MDX 1379], and melanoma vaccine monotherapy in HLA-A2 0201-positive patients with previously treated unresectable stage III or IV melanoma

Next Previous
Trial Profile

A randomized, double-blind, multicenter study comparing MDX-010 [ipilimumab] monotherapy, MDX-010 in combination with a melanoma peptide vaccine [MDX 1379], and melanoma vaccine monotherapy in HLA-A2 0201-positive patients with previously treated unresectable stage III or IV melanoma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; MDX 1379
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Bristol-Myers Squibb; Medarex

Most Recent Events

  • 12 Oct 2017 Results of pooled data from three trial (CheckMate-067, CheckMate-037 and MDX010-20) assessing utility values across treatments and lines of treatment using data in advanced melanoma for two immuno-oncology agents, nivolumab and ipilimumab, were presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
  • 13 May 2016 Results of comparison of overall survival data for ipilimumab, vemurafenib and dacarbazine from three trials including this published in the BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
  • 01 Dec 2015 Results related to immunoregulatory predictors of efficacy from NCT00094653 and NCT00495066 published in the Cancer Research.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top